ALK Alkemy Capital Investments Plc

 
TIDMALK TIDMB 
 

2024 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKBLF):

   -- 11 January 2024: Silent period 
 
   -- 8 February 2024: Annual report 2023 
 
   --  14 March 2024 at 4.00 p.m.: Annual General Meetingto be held at 
        ALK        Bøge Allé 12970 Hørsholm, Denmark Written 
      requests to have specific business transacted at the AGM will be included 
      in theagenda if received by the company on31 January 2024 at the 
      latest(may be emailed to investor@alk.net) 
 
   -- 5 April 2024: Silent period 
 
   -- 3 May 2024: Three-month interim report (Q1) 2024 
 
   -- 26 July 2024: Silent period 
 
   -- 23 August 2024: Six-month interim report (Q2) 2024 
 
   -- 17 October 2024: Silent period 
 
   -- 14 November 2024: Nine-month interim report (Q3) 2024 

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Maiken Riise Andersen, tel. +45 5054 1434

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.

Attachment

   -- InvestorNews_20Dec23_FinancialCalendar 
      https://ml-eu.globenewswire.com/Resource/Download/0975be56-0ef8-4846-a4a0-5f87b81db652 
 
 
 

(END) Dow Jones Newswires

December 20, 2023 04:45 ET (09:45 GMT)

Alkemy Capital Investments (LSE:ALK)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024

Alkemy Capital Investments (LSE:ALK)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024